Manmohan R. Leleti

589 citations

31 papers · 262 indexed · h-index 7

Co-authors: Jay P. Powers Lisa Seitz Joanne B.L. Tan Juan C. Jaén Penglie Zhang Pirow Bekker Linda Ertl Shichang Miao
Topics: Adenosine and Purinergic Signaling (18 papers)Nanoplatforms for cancer theranostics (12 papers)Click Chemistry and Applications (6 papers)
Cited by: Physiology Immunology Nephrology
Journals: PLoS ONE Cancer Research The FASEB Journal
Partner nations: United States Germany

In The Last Decade

Manmohan R. Leleti

27 papers receiving 243 citations

Peers

Countries citing papers authored by Manmohan R. Leleti

Since Specialization

Citations

This map shows the geographic impact of Manmohan R. Leleti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manmohan R. Leleti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manmohan R. Leleti more than expected).

Fields of papers citing papers by Manmohan R. Leleti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manmohan R. Leleti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manmohan R. Leleti. The network helps show where Manmohan R. Leleti may publish in the future.

Co-authorship network of co-authors of Manmohan R. Leleti

This figure shows the co-authorship network connecting the top 25 collaborators of Manmohan R. Leleti. A scholar is included among the top collaborators of Manmohan R. Leleti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manmohan R. Leleti. Manmohan R. Leleti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a Scalable Synthesis of Casdatifan (AB521), a Potent, Selective, Clinical-Stage Inhibitor of HIF-2α 2025 ·Organic Process Research & Development ·(unknown),Artur K. Mailyan,Guillaume Mata,Joel W. Beatty,(unknown),(unknown),Jarosław Kalisiak,Brandon R. Rosen,(unknown),(unknown),(unknown),Zhang Wang,(unknown),Anh Tran,Manmohan R. Leleti,Jay P. Powers,Kenneth V. Lawson	1
2	Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors 2025 ·Journal of Medicinal Chemistry ·(unknown),(unknown),(unknown),Manjunath Lamani,(unknown),Ehesan U. Sharif,Joice Thomas,Pradeep Nareddy,Gang Zhao,Yu Chen,Xiaoning Zhao,David A. Green,(unknown),Lixia Jin,(unknown),Ester Fernández‐Salas,Jay P. Powers,Manmohan R. Leleti,Dillon H. Miles	1
3	Abstract 256: Dual A2aR/A2bR antagonism with etrumadenant (AB928) eliminates the suppressive effects of adenosine on immune and cancer cells in the tumor microenvironment 2022 ·Cancer Research ·Sachie Marubayashi,Bindi Patel,(unknown),(unknown),(unknown),Jenna L. Jeffrey,Manmohan R. Leleti,Jay P. Powers,(unknown),Daniel DiRenzo	2
4	Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors 2021 ·Journal of Medicinal Chemistry ·Ehesan U. Sharif,Jarosław Kalisiak,Kenneth V. Lawson,Dillon H. Miles,(unknown),Erick A. Lindsey,Brandon R. Rosen,Laurent Debien,Ada Chen,Xiaoning Zhao,Stephen W. Young,Nigel P.C. Walker,Norbert Sträter,Emma Rose Scaletti,Lixia Jin,Guifen Xu,Manmohan R. Leleti,Jay P. Powers	26
5	Abstract 1206: Discovery and characterization of AB521, a novel, potent, and selective hypoxia-inducible factor (HIF)-2α inhibitor 2021 ·Cancer Research ·Kenneth V. Lawson,(unknown),Artur K. Mailyan,(unknown),Joel W. Beatty,(unknown),(unknown),(unknown),Guillaume Mata,Zhang Wang,Xuelei Yan,Lixia Jin,(unknown),(unknown),Jennifer Au,(unknown),Stephen W. Young,Matthew J. Walters,Manmohan R. Leleti,Jay P. Powers	3
6	Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors for cancer therapy 2020 ·European Journal of Cancer ·Dillon H. Miles,(unknown),(unknown),(unknown),(unknown),Manmohan R. Leleti,Xiao‐Fan Zhao,Lixia Jin,Stephen W. Young,Matthew J. Walters,Jay P. Powers	1
7	Development of a Scalable Method for Manufacturing the Central Core of CD73 Inhibitor AB680 2020 ·Organic Process Research & Development ·(unknown),Xuelei Yan,Anh Tran,Rebecca L. Grange,(unknown),Jarosław Kalisiak,Kenneth V. Lawson,(unknown),Manmohan R. Leleti,Jay P. Powers	4
8	Development of a Scalable and Practical Synthesis of AB928, a Dual A_2a/A_2b Receptor Antagonist 2020 ·Organic Process Research & Development ·Ehesan U. Sharif,Dillon H. Miles,Brandon R. Rosen,Jenna L. Jeffrey,Laurent Debien,Jay P. Powers,Manmohan R. Leleti	3
9	Abstract A10: The dual A2aR/A2bR antagonist AB928 reverses adenosine-mediated immune suppression and inhibits tumor growth in vivo 2020 ·Cancer Immunology Research ·Daniel DiRenzo,(unknown),(unknown),Devika Ashok,(unknown),Jenna L. Jeffrey,Manmohan R. Leleti,Joanne B.L. Tan,Lisa Seitz,(unknown),Jay P. Powers,Matthew J. Walters	2
10	Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression 2019 ·Cancer Immunology Research ·Daniel DiRenzo,(unknown),Joanne B.L. Tan,Dillon H. Miles,Manmohan R. Leleti,Timothy Park,Ferdie Soriano,(unknown),Jenna L. Jeffrey,Ehesan U. Sharif,Brandon R. Rosen,Ulrike Schindler,Jay P. Powers,Matthew J. Walters	7
11	Abstract 3862: AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer 2019 ·(unknown),Yu Chen,(unknown),(unknown),(unknown),(unknown),(unknown),Manmohan R. Leleti,(unknown),(unknown),Jie Chen,(unknown),(unknown),Lixia Jin,Stephen W. Young,Matthew J. Walters,Ulrike Schindler,Jay P. Powers	1
12	Abstract 3862: AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer 2019 ·Cancer Research ·(unknown),Yu Chen,(unknown),(unknown),(unknown),(unknown),(unknown),Manmohan R. Leleti,(unknown),(unknown),Jie Chen,(unknown),(unknown),Lixia Jin,Stephen W. Young,Matthew J. Walters,Ulrike Schindler,Jay P. Powers	1
13	Final results of the phase I study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response 2018 ·Annals of Oncology ·Lisa Seitz,(unknown),Manmohan R. Leleti,Jay P. Powers,Brandon R. Rosen,Dillon H. Miles,Ehesan U. Sharif,(unknown),(unknown),S. R. Young,(unknown),(unknown),Joyson Karakunnel,(unknown)	2
14	Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers 2018 ·Investigational New Drugs ·Lisa Seitz,Lixia Jin,Manmohan R. Leleti,Devika Ashok,Jenna L. Jeffrey,(unknown),Renger G. Tiessen,Gerhard Arold,Joanne B.L. Tan,Jay P. Powers,Matthew J. Walters,Joyson Karakunnel	48
15	Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control 2018 ·Cancer Research ·(unknown),(unknown),Joanne B.L. Tan,Daniel DiRenzo,F Yin,Dillon H. Miles,Manmohan R. Leleti,(unknown),Ferdie Soriano,(unknown),Ulrike Schindler,Jay P. Powers	9
16	Abstract 2640: Small-molecule inhibitors of CD73, CD39 and A2aR: Three anti-cancer targets in the ATP/adenosine signaling pathway 2017 ·Cancer Research ·Ulrike Schindler,Joanne B.L. Tan,(unknown),Annette Becker,F Yin,Ada Chen,Yu Chen,(unknown),Steve Young,Manmohan R. Leleti,Jay P. Powers,Juan C. Jaén	1
17	Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study 2016 ·PLoS ONE ·Pirow Bekker,Daniel J. Dairaghi,Lisa Seitz,Manmohan R. Leleti,Yu Wang,Linda Ertl,Trageen Baumgart,Sarah Shugarts,Lisa Lohr,(unknown),Shichang Miao,Yibin Zeng,Pingchen Fan,Penglie Zhang,Daniel E. Johnson,Jay P. Powers,Juan C. Jaén,Israel Charo,Thomas J. Schall	115
18	Abstract PR10: Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors 2016 ·Cancer Immunology Research ·Juan C. Jaén,Jay P. Powers,Ada Chen,Manmohan R. Leleti,(unknown),Ulrike Schindler,Joanne B.L. Tan,Steve Young,Shin‐Heng Chiou,Laurent Debien	2
19	Novel small-molecule inhibitors of ecto-nucleotidase CD73: Activation of human CD8+ T cells and effects on tumor growth and immune parameters in experimental tumor models 2016 ·European Journal of Cancer ·(unknown),(unknown),Manmohan R. Leleti,(unknown),David J. C. Miles,(unknown),Joyce T. Tan,(unknown),(unknown),Steven Young,Joaquín Jaén	1
20	FRI0002 Inhibition of chemokine receptors ccr1 and ccr6 as promising therapies for rheumatoid arthritis 2013 ·Annals of the Rheumatic Diseases ·Juan C. Jaén,Daniel J. Dairaghi,Manmohan R. Leleti,Jay P. Powers,(unknown),(unknown),Thomas J. Schall	2

About Manmohan R. Leleti

Manmohan R. Leleti is a scholar working on Physiology, Oncology and Biotechnology, having authored 31 papers that have together received 262 indexed citations. Recurring topics across this work include Adenosine and Purinergic Signaling (18 papers), Nanoplatforms for cancer theranostics (12 papers) and Click Chemistry and Applications (6 papers). The work is most often cited by research in Physiology (105 citations), Immunology (112 citations) and Nephrology (28 citations). Manmohan R. Leleti has collaborated with scholars based in United States and Germany. Frequent co-authors include Jay P. Powers, Lisa Seitz, Joanne B.L. Tan, Juan C. Jaén, Penglie Zhang, Pirow Bekker, Linda Ertl, Shichang Miao, Yu Wang and Lisa Lohr. Their work appears in journals such as PLoS ONE, Cancer Research and The FASEB Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact